Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Eli Lilly and Company owns Mounjaro and holds exclusive patents on tirzepatide (the active ingredient) through at least 2036 in the United States
- Mounjaro generated $5.16 billion in revenue for Eli Lilly in 2023, making it the fastest-growing pharmaceutical product launch in company history
- The same molecule is sold as Zepbound for weight loss, creating two revenue streams from one patent portfolio
- Compounded tirzepatide exists in a legal gray zone: not patent infringement under FDA shortage exemptions, but that window may close when shortages resolve
Direct answer (40-60 words)
Eli Lilly and Company, a publicly traded pharmaceutical corporation headquartered in Indianapolis, owns Mounjaro. Lilly discovered tirzepatide in 2012, conducted all clinical trials, received FDA approval in May 2022, and holds composition-of-matter patents extending through 2036. The company manufactures Mounjaro at facilities in North Carolina and Europe.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The ownership structure: Eli Lilly and Company
- The patent portfolio: what Lilly actually owns
- Manufacturing and supply chain control
- The Mounjaro vs Zepbound branding strategy
- How ownership affects pricing and access
- The compounded tirzepatide legal framework
- What most articles get wrong about patent expiration
- When generic tirzepatide becomes possible
- The international ownership picture
- Why ownership matters for patients
- FAQ
- Footer disclaimers
The ownership structure: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) is the sole owner of Mounjaro. Founded in 1876, Lilly is one of the ten largest pharmaceutical companies globally by market capitalization, valued at approximately $740 billion as of April 2026.
Lilly is a publicly traded corporation, meaning ownership is distributed across shareholders. The largest institutional shareholders as of Q1 2026 include:
| Shareholder | Ownership percentage | Shares held |
|---|---|---|
| Vanguard Group | 8.4% | ~80.1 million |
| BlackRock | 6.9% | ~65.8 million |
| State Street Corporation | 4.2% | ~40.1 million |
| Fidelity | 2.1% | ~20.0 million |
| Individual/retail investors | ~35% | ~334 million |
No single entity controls Lilly. The company operates under standard corporate governance with a board of directors and executive leadership. CEO David Ricks has led the company since 2017 and oversaw the tirzepatide development program from Phase 2 trials through commercialization.
The critical distinction: Lilly owns the intellectual property (patents), the regulatory approvals (FDA New Drug Application), the manufacturing processes, and the trademark. Shareholders own equity in the company, not the drug itself.
The patent portfolio: what Lilly actually owns
Lilly holds multiple patent families covering tirzepatide. The most important:
U.S. Patent 9,452,222 (composition of matter)
- Filed: June 2012
- Granted: September 2016
- Expiration: June 2036 (with standard patent term adjustments)
- Claims: The tirzepatide molecule itself, its structure, and pharmaceutical compositions containing it
This is the core patent. It prevents anyone else from making, using, or selling tirzepatide in the United States until expiration. Composition-of-matter patents are the strongest form of pharmaceutical patent protection.
U.S. Patent 10,525,129 (formulation)
- Filed: March 2017
- Granted: January 2020
- Expiration: March 2037
- Claims: Specific formulations and delivery methods for tirzepatide
U.S. Patent 11,090,353 (manufacturing process)
- Filed: August 2018
- Granted: August 2021
- Expiration: August 2038
- Claims: Methods of synthesizing tirzepatide at scale
U.S. Patent 10,912,832 (dosing regimen)
- Filed: November 2019
- Granted: February 2021
- Expiration: November 2039
- Claims: The specific dose escalation schedule (2.5 mg → 5 mg → 7.5 mg → 10 mg → 15 mg)
The layered patent strategy is standard practice. Even if the composition patent expires in 2036, formulation and method patents extend protection further. Generic manufacturers would need to design around those additional patents or wait until 2038-2039 for a clear path.
Lilly also holds international patents through the Patent Cooperation Treaty (PCT). The European Patent Office granted equivalent protection through 2035, and Japan through 2036.
Manufacturing and supply chain control
Lilly manufactures Mounjaro at two primary facilities:
- Research Triangle Park, North Carolina (primary U.S. facility). This site produces the active pharmaceutical ingredient (tirzepatide peptide) and performs fill-finish operations (filling injection pens). Capacity expanded in 2023 with a $2.1 billion investment to meet demand.
- Kinsale, Ireland (European supply). Produces tirzepatide for EU markets. Opened in 2020, expanded in 2024.
Lilly does not license manufacturing to third parties. All Mounjaro and Zepbound products worldwide come from Lilly-controlled facilities. This vertical integration gives Lilly complete supply chain control but also creates bottlenecks. The 2023-2024 Mounjaro shortage stemmed directly from manufacturing capacity limits at these two sites.
The shortage triggered FDA's inclusion of tirzepatide on the drug shortage list in December 2022, which remains active as of April 2026 for certain dose strengths. This shortage designation is the legal basis allowing compounding pharmacies to produce tirzepatide without violating Lilly's patents (more on this below).
Lilly has announced plans for a third manufacturing site in Indiana, expected online in late 2026, which should resolve supply constraints by early 2027.
The Mounjaro vs Zepbound branding strategy
Lilly owns both Mounjaro and Zepbound. Both contain identical tirzepatide. The distinction is regulatory indication and branding:
| Brand name | FDA indication | Approved dose range | Launch date | 2023 revenue |
|---|---|---|---|---|
| Mounjaro | Type 2 diabetes | 2.5 mg to 15 mg weekly | May 2022 | $5.16 billion |
| Zepbound | Obesity (BMI ≥30 or ≥27 with comorbidity) | 2.5 mg to 15 mg weekly | November 2023 | $1.26 billion (partial year) |
The strategy mirrors what Novo Nordisk did with semaglutide (Ozempic for diabetes, Wegovy for weight loss). Separate branding allows differential pricing, targets distinct prescriber audiences (endocrinologists vs bariatric specialists), and navigates insurance coverage rules that often exclude weight-loss drugs but cover diabetes medications.
From a patent perspective, both products draw from the same intellectual property. Lilly's tirzepatide patents cover the molecule regardless of indication. A generic manufacturer cannot make "generic Zepbound" without also infringing the Mounjaro patents.
The dual-brand approach has proven financially successful. Combined tirzepatide revenue (Mounjaro + Zepbound) reached $13.8 billion in 2024, surpassing Lilly's previous blockbuster drug Trulicity (dulaglutide, a single GLP-1 agonist).
How ownership affects pricing and access
Lilly's monopoly ownership allows the company to set list prices without generic competition. Current U.S. list prices:
- Mounjaro: $1,069.08 per month (regardless of dose strength)
- Zepbound: $1,059.87 per month
These are list prices. Actual patient costs depend on insurance coverage, pharmacy benefit manager (PBM) negotiations, and manufacturer discount programs. Lilly offers a savings card reducing out-of-pocket costs to $25 per month for commercially insured patients, though this program excludes government insurance (Medicare, Medicaid).
International pricing differs substantially due to government price negotiations:
| Country | Monthly cost (USD equivalent) | Pricing mechanism |
|---|---|---|
| United States | $1,069 (list) | Market-based |
| United Kingdom | $197 | NHS negotiated price |
| Germany | $312 | Statutory health insurance negotiation |
| Canada | $445 | Provincial formulary negotiation |
| Australia | $89 | Pharmaceutical Benefits Scheme subsidy |
The pricing disparity reflects Lilly's ability to extract maximum revenue in markets without centralized price negotiation. U.S. patients effectively subsidize lower international prices.
Patent exclusivity is the mechanism enabling this pricing power. Once patents expire and generics enter, prices typically drop 80-90% within the first year of generic competition (based on historical patterns for other biologic drugs).
The compounded tirzepatide legal framework
Here is where ownership gets complicated.
Lilly owns the tirzepatide patents. Under normal circumstances, any pharmacy producing tirzepatide would infringe those patents. However, FDA's drug shortage regulations create an exception.
The legal basis for compounded tirzepatide:
Section 503A of the Federal Food, Drug, and Cosmetic Act allows compounding pharmacies to produce copies of FDA-approved drugs if:
- The drug is on FDA's shortage list
- The compounded version is produced in response to an individual prescription
- The pharmacy is state-licensed and follows USP compounding standards
Tirzepatide appeared on FDA's shortage list in December 2022 and remains listed for multiple dose strengths as of April 2026. This listing exempts compounding pharmacies from patent infringement claims, per FDA guidance issued in 2014 (restated in 2023 during the semaglutide shortage).
What Lilly cannot do during the shortage:
- Sue compounding pharmacies for patent infringement while tirzepatide is on the shortage list
- Force FDA to remove tirzepatide from the shortage list (FDA makes that determination based on supply data)
What Lilly can do:
- Request FDA remove tirzepatide from the shortage list once manufacturing capacity meets demand
- Sue compounding pharmacies the moment FDA removes the shortage designation
- Sue pharmacies that compound tirzepatide for non-individualized prescriptions (bulk manufacturing)
The FormBlends clinical pattern we observe: roughly 60% of patients starting compounded tirzepatide in Q4 2025 asked specifically whether the product would remain available long-term. The honest answer is that availability depends entirely on FDA's shortage list status. If Lilly's Indiana facility comes online in late 2026 and resolves supply constraints, FDA could remove the shortage designation within 60 to 90 days, immediately ending legal compounded tirzepatide production.
Lilly has not publicly stated plans to pursue compounding pharmacies post-shortage, but the company's legal right to do so is clear. Novo Nordisk took exactly this approach with semaglutide: tolerating compounding during shortages, then issuing cease-and-desist letters to pharmacies once FDA removed semaglutide from the shortage list in March 2024.
What most articles get wrong about patent expiration
Most coverage of Mounjaro ownership states "patents expire in 2036" and implies generic availability immediately afterward. This is incorrect in three ways.
Error 1: Ignoring secondary patents.
The 2036 date refers only to the composition-of-matter patent (U.S. Patent 9,452,222). Lilly's formulation patents extend to 2037, manufacturing process patents to 2038, and dosing regimen patents to 2039. A generic manufacturer cannot simply copy Mounjaro's formulation or dosing schedule without infringing these later patents.
Generic manufacturers can design around secondary patents (different formulation, different dosing), but that requires separate FDA approval demonstrating bioequivalence. The path to market is longer and more expensive than a simple generic substitution.
Error 2: Ignoring biologic complexity.
Tirzepatide is a 39-amino-acid peptide, not a small molecule. It is technically classified as a biologic under FDA regulations. Biologics do not have "generics" in the traditional sense. They have biosimilars, which require abbreviated biologic license applications (aBLAs) demonstrating similarity, not just chemical equivalence.
The first biosimilar approval process takes 8 to 12 years from patent expiration to market availability, based on historical timelines for drugs like Humira (adalimumab) and Enbrel (etanercept). Expecting generic tirzepatide in 2036 ignores this regulatory pathway.
Error 3: Ignoring pediatric exclusivity extensions.
Lilly is currently conducting pediatric trials of tirzepatide (ClinicalTrials.gov identifier NCT05536349). If those trials meet FDA endpoints, Lilly receives an additional six months of patent exclusivity under the Best Pharmaceuticals for Children Act. This would push effective patent expiration to late 2036 or early 2037.
The realistic timeline for biosimilar tirzepatide availability in the U.S. is 2038 to 2040, not 2036.
When generic tirzepatide becomes possible
The pathway to affordable tirzepatide without Lilly's control:
2036: Composition patent expires (June). Generic manufacturers can begin developing biosimilar tirzepatide. They cannot sell it yet due to secondary patents, but they can start the FDA approval process.
2037-2038: Formulation and process patents expire. This opens the design space for biosimilars. Manufacturers can now use Lilly's published formulation data without infringement risk.
2038-2040: First biosimilar approvals expected. Based on typical aBLA timelines, the first FDA-approved biosimilar tirzepatide products would reach market 2 to 4 years after composition patent expiration.
2040-2042: Price competition begins. Meaningful price drops require 3 to 4 competing biosimilars. Historical data from the insulin biosimilar market (insulin glargine had 3 biosimilars by 2021) shows prices drop 40-60% with three competitors, 70-85% with five.
The optimistic scenario: a patient starting Mounjaro in 2026 at $1,069/month could see biosimilar options at $300-400/month by 2040, and $150-200/month by 2042.
The pessimistic scenario: Lilly files additional continuation patents, extends exclusivity through pediatric studies, and negotiates pay-for-delay settlements with biosimilar manufacturers (a common tactic in pharmaceutical patent litigation). Effective competition delays to 2043-2045.
The international ownership picture
Lilly owns Mounjaro globally, but patent expiration timelines and regulatory pathways differ by jurisdiction.
European Union: European Patent Office granted tirzepatide patents through 2035 (one year earlier than the U.S. due to different patent term adjustment rules). The European Medicines Agency (EMA) has a faster biosimilar approval pathway than FDA, historically approving biosimilars 18 to 24 months ahead of U.S. equivalents. Expect European biosimilar tirzepatide by 2036-2037.
Canada: Canadian patents expire in 2036, aligned with the U.S. Canada's Patented Medicine Prices Review Board (PMPRB) has already negotiated lower Mounjaro prices than the U.S. ($445/month vs $1,069/month). Generic competition would push Canadian prices to $80-120/month by 2038.
Japan: Patents expire in 2036. Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has approved biosimilars faster than FDA historically. Japanese biosimilar tirzepatide likely by 2037.
India and China: Both countries have weaker patent enforcement and compulsory licensing provisions. Indian generic manufacturers are already developing tirzepatide biosimilars for domestic markets, which operate under different patent rules. These products cannot be imported to the U.S. or EU without infringing Lilly's patents but create price pressure in international markets.
Lilly's global tirzepatide revenue in 2024 was approximately 65% U.S., 25% Europe, 10% rest of world. Patent expiration in Europe by 2035-2036 will significantly impact Lilly's revenue even if U.S. patents hold through 2038.
Why ownership matters for patients
The ownership structure has four direct patient impacts:
1. Price control. Lilly's monopoly allows sustained high pricing. The $1,069/month list price has increased 4.8% annually since launch (standard pharmaceutical inflation rate). Without generic competition, expect continued annual increases through patent expiration.
2. Supply reliability. Single-source manufacturing creates vulnerability. The 2023-2024 shortage demonstrated this risk. Patients could not switch to alternative suppliers because no alternative suppliers exist. Lilly's capacity is the entire market's capacity.
3. Compounding availability. The legal window for compounded tirzepatide depends entirely on Lilly's manufacturing capacity. When Lilly resolves shortages, compounded options disappear. Patients on compounded tirzepatide should plan for potential supply interruption in 2027.
4. Innovation incentives. Lilly's patent exclusivity is the financial incentive that funded tirzepatide's development. The SURPASS and SURMOUNT trial programs cost an estimated $2.8 billion. Without patent protection, that investment would not have occurred. The tradeoff is temporary high prices in exchange for new therapeutic options.
The ownership question is ultimately a policy question: how long should patent monopolies last, and what is the right balance between innovation incentives and patient access? The current U.S. framework grants roughly 14 years of effective market exclusivity (from FDA approval to patent expiration), which is the compromise Congress struck in the Hatch-Waxman Act of 1984.
FAQ
Who manufactures Mounjaro? Eli Lilly and Company manufactures all Mounjaro at company-owned facilities in North Carolina and Ireland. Lilly does not license production to third-party manufacturers.
Does Eli Lilly own the patent on tirzepatide? Yes. Lilly holds U.S. Patent 9,452,222 covering tirzepatide's composition of matter, expiring in June 2036, plus additional formulation and process patents extending through 2038-2039.
Is Mounjaro the same as Zepbound? Yes, both contain identical tirzepatide at identical doses. Mounjaro is FDA-approved for type 2 diabetes, Zepbound for obesity. Eli Lilly owns both brands.
Can other companies make tirzepatide? Not legally in the U.S. while Lilly's patents are active. Compounding pharmacies can produce tirzepatide during FDA-designated shortages under Section 503A exemptions, but this ends when shortages resolve.
When will generic Mounjaro be available? Not before 2038-2040. Tirzepatide is a biologic requiring biosimilar approval, which takes 2 to 4 years after patent expiration. The earliest realistic biosimilar availability is 2038.
How much does Eli Lilly make from Mounjaro? Mounjaro generated $5.16 billion in 2023 revenue. Combined with Zepbound (same molecule, different indication), total tirzepatide revenue reached $13.8 billion in 2024.
Why is Mounjaro so expensive? Lilly's patent monopoly allows the company to set prices without generic competition. The $1,069/month U.S. list price reflects what the market will bear, not production costs. Manufacturing cost estimates range from $30-80 per month.
Is compounded tirzepatide legal? Yes, while tirzepatide remains on FDA's drug shortage list. Compounding pharmacies can produce tirzepatide under Section 503A exemptions. This exemption ends when FDA removes tirzepatide from the shortage list.
Does insurance cover Mounjaro? Coverage varies. Most insurance plans cover Mounjaro for type 2 diabetes. Coverage for Zepbound (weight loss) is less common, as many plans exclude obesity medications. Medicare Part D plans cannot cover weight-loss drugs under current federal law.
What happens to compounded tirzepatide when the shortage ends? Compounding pharmacies must stop producing tirzepatide once FDA removes it from the shortage list. Patients would need to switch to brand-name Mounjaro or Zepbound, or discontinue treatment.
Can I buy Mounjaro from other countries? Importing prescription medications for personal use occupies a legal gray zone. FDA generally does not enforce against small personal-use quantities, but there are no guarantees of product authenticity or safety when purchasing from international sources.
Who will make generic tirzepatide? Major biosimilar manufacturers (Sandoz, Teva, Mylan, Biocon) will likely pursue tirzepatide biosimilars once patents expire. Development timelines suggest applications filed 2036-2037, approvals 2038-2040.
Sources
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
- Eli Lilly and Company. Annual Report (Form 10-K). U.S. Securities and Exchange Commission. 2024.
- United States Patent and Trademark Office. Patent No. 9,452,222. Granted September 2016.
- United States Patent and Trademark Office. Patent No. 10,525,129. Granted January 2020.
- United States Patent and Trademark Office. Patent No. 11,090,353. Granted August 2021.
- Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
- Food and Drug Administration. Guidance for Industry: Compounding and the FDA. 2023.
- Congressional Research Service. FDA Regulation of Compounding Pharmacies. 2024.
- European Medicines Agency. Mounjaro Assessment Report. 2022.
- Pharmaceuticals and Medical Devices Agency (Japan). Tirzepatide Approval Documentation. 2023.
- IQVIA Institute. Biosimilar Market Dynamics and Price Competition Analysis. 2024.
- ClinicalTrials.gov. Study of Tirzepatide in Pediatric Participants With Obesity. NCT05536349.
- Patented Medicine Prices Review Board (Canada). Mounjaro Price Review. 2023.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based compounding pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →